3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Hemangioma
9
Melanoma
6
Hemangioma, Capillary
6
Breast Neoplasms
5
Sarcoma
3
Hemangiosarcoma
3
Fallopian Tube Neoplasms
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Multiple Myeloma
2
Hemangioma, Cavernous, Central Nervous System
2
Carcinoma, Ovarian Epithelial
2
von Hippel-Lindau Disease
1
Uterine Cervical Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ulcer
1
Tuberous Sclerosis
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Spinal Cord Neoplasms
1
Smoldering Multiple Myeloma
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Recurrent respiratory papillomatosis
1
Recurrence
1
Papilloma
1
Ovarian Neoplasms
1
Neuroblastoma
1
Interventions
Radiotherapy
6
Doxorubicin
5
Nivolumab
4
pembrolizumab
3
Sunitinib
3
Ifosfamide
3
Gemcitabine
3
Docetaxel
3
pazopanib
2
Radiation Dose Hypofractionation
2
Radiation
2
Methotrexate
2
Ipilimumab
2
Cisplatin
2
CTLA-4 Antigen
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
tremelimumab
1
toripalimab
1
temsirolimus
1
spartalizumab
1
sintilimab
1
ribociclib
1
regorafenib
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
itacitinib
1
fludarabine
1
eribulin
1
durvalumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Histiocytoma, Malignant Fibrous
×
Propranolol
×
Clear all
NCT05961761
2023-07-27
PROPANE
Herlev and Gentofte Hospital
Phase 2
Recruiting
80 enrolled